Shanghai Fosun Pharmaceutical (Group) Co. Ltd. has announced that it will hold its 2026 first extraordinary general meeting on February 27, 2026, at the Sky Fortune Boutique Hotel Shanghai. During the meeting, shareholders will consider and vote on several key proposals, including: the compliance of the spin-off of Fosun Adgenvax (a subsidiary of the company) for listing on the Main Board of the Hong Kong Stock Exchange; the authorisation to the Board or its authorised persons to deal with matters related to the proposed spin-off listing; and the provision of assured entitlements to H Shareholders of the company only in connection with the spin-off of Fosun Adgenvax.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260204-12014630), on February 04, 2026, and is solely responsible for the information contained therein.